Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 4
2010 1
2011 1
2012 3
2013 4
2014 5
2015 1
2016 3
2017 6
2018 8
2019 7
2020 4
2021 4
2022 1
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.
Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, Blank CU, Hartemink KJ, Monkhorst K, Haanen JBAG, Schumacher TN, Thommen DS. Voabil P, et al. Among authors: de bruijn m. Nat Med. 2021 Jul;27(7):1250-1261. doi: 10.1038/s41591-021-01398-3. Epub 2021 Jul 8. Nat Med. 2021. PMID: 34239134
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, Klaase L, de Bruijn M, van Nimwegen M, van Tienhoven T, van Ijcken W, Boon L, van der Schoot J, Verdoes M, Scheeren F, van der Burg SH, Lambrecht BN, Stadhouders R, Dammeijer F, Aerts J, van Hall T. van Gulijk M, et al. Among authors: de bruijn m. Sci Immunol. 2023 May 19;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173. Epub 2023 May 19. Sci Immunol. 2023. PMID: 37205768
An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibáñez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Müller J, Logtenberg MEW, de Bruijn M, Levy P, Körner PR, Goding CR, Schumacher TN, Marine JC, Agami R, Peeper DS. Kenski JCN, et al. Among authors: de bruijn m. Cell Rep Med. 2023 Feb 21;4(2):100941. doi: 10.1016/j.xcrm.2023.100941. Cell Rep Med. 2023. PMID: 36812891 Free PMC article.
Protocol for ex vivo culture of patient-derived tumor fragments.
Roelofsen LM, Voabil P, de Bruijn M, Herzig P, Zippelius A, Schumacher TN, Thommen DS. Roelofsen LM, et al. Among authors: de bruijn m. STAR Protoc. 2023 May 6;4(2):102282. doi: 10.1016/j.xpro.2023.102282. Online ahead of print. STAR Protoc. 2023. PMID: 37149855 Free PMC article.
Type-2 CD8+ T-cell formation relies on interleukin-33 and is linked to asthma exacerbations.
van der Ploeg EK, Krabbendam L, Vroman H, van Nimwegen M, de Bruijn MJW, de Boer GM, Bergen IM, Kool M, Tramper-Standers GA, Braunstahl GJ, Huylebroeck D, Hendriks RW, Stadhouders R. van der Ploeg EK, et al. Among authors: de bruijn mjw. Nat Commun. 2023 Aug 23;14(1):5137. doi: 10.1038/s41467-023-40820-x. Nat Commun. 2023. PMID: 37612281 Free PMC article.
Niche-expressed Galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation.
Pelletier J, Balzano M, Destin J, Montersino C, Delahaye MC, Marchand T, Bailly AL, Bardin F, Coppin E, Goubard A, Castellano R, de Bruijn MJW, Rip J, Collette Y, Dubreuil P, Tarte K, Broccardo C, Hendriks RW, Schiff C, Vey N, Aurrand-Lions M, Mancini SJC. Pelletier J, et al. Among authors: de bruijn mjw. iScience. 2023 Mar 11;26(4):106385. doi: 10.1016/j.isci.2023.106385. eCollection 2023 Apr 21. iScience. 2023. PMID: 37009219 Free PMC article.
Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases.
van der Ploeg EK, Golebski K, van Nimwegen M, Fergusson JR, Heesters BA, Martinez-Gonzalez I, Kradolfer CMA, van Tol S, Scicluna BP, de Bruijn MJW, de Boer GM, Tramper-Stranders GA, Braunstahl GJ, van IJcken WFJ, Nagtegaal AP, van Drunen CM, Fokkens WJ, Huylebroeck D, Spits H, Hendriks RW, Stadhouders R, Bal SM. van der Ploeg EK, et al. Among authors: de bruijn mjw. Sci Immunol. 2021 Jan 29;6(55):eabd3489. doi: 10.1126/sciimmunol.abd3489. Sci Immunol. 2021. PMID: 33514640
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
Kaptein P, Jacoberger-Foissac C, Dimitriadis P, Voabil P, de Bruijn M, Brokamp S, Reijers I, Versluis J, Nallan G, Triscott H, McDonald E, Tay J, Long GV, Blank CU, Thommen DS, Teng MWL. Kaptein P, et al. Among authors: de bruijn m. Sci Transl Med. 2022 Apr 27;14(642):eabj9779. doi: 10.1126/scitranslmed.abj9779. Epub 2022 Apr 27. Sci Transl Med. 2022. PMID: 35476594
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OBJ. Rip J, et al. Among authors: de bruijn mjw. Front Immunol. 2019 Jan 30;10:95. doi: 10.3389/fimmu.2019.00095. eCollection 2019. Front Immunol. 2019. PMID: 30761150 Free PMC article.
56 results